Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephanie Boring

Physician Assistant Edmore, MI Physician Assistant

NPI 1942398987 CMS profile 10964247

1021 E Main St, Edmore, MI 48829

Open in the dashboard

General payments

$6,565

354 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Boring of Edmore, MI is reported in the CMS Open Payments database as having received $6,565 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,962 99
2024 General $1,696 94
2023 General $1,084 62
2022 General $927 51
2021 General $896 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Boring
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stephanie Boring were reported at $1,962. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stephanie Boring Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $896 $132 $37–$438 $132
2022 $927 $155 $48–$522 $149
2023 $1,084 $167 $52–$557 $160
2024 $1,696 $178 $55–$600 $164
2025 $1,962 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,805 104 payments
  2. Novo Nordisk Inc $613 33 payments
  3. AstraZeneca Pharmaceuticals LP $475 26 payments
  4. Lilly USA, LLC $473 32 payments
  5. Amgen Inc. $339 20 payments
  6. ITI, Inc. $282 11 payments
  7. Astellas Pharma US Inc $233 8 payments
  8. Otsuka America Pharmaceutical, Inc. $232 10 payments
  9. Exact Sciences Corporation $213 11 payments
  10. Lundbeck LLC $149 6 payments
  11. Other $1,750 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,465 353 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $1,082 53 payments
  2. UBRELVY $789 39 payments
  3. VRAYLAR $387 27 payments
  4. RYBELSUS $355 19 payments
  5. Ozempic $340 18 payments
  6. AIRSUPRA $252 12 payments
  7. REXULTI $232 10 payments
  8. KRYSTEXXA $227 14 payments
  9. MOUNJARO $226 16 payments
  10. FARXIGA $209 11 payments
  11. Other $4,342 240 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 92 drugs

Part D claims

3,102

Median for Physician Assistant: 241

Drug cost

$403,948

Median for Physician Assistant: $4,110

Branded share of claims

22.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 76 $93,128
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 52 $50,155
Rexulti Brexpiprazole Brand 17 $41,156
Ozempic Semaglutide Brand 25 $36,740
Jardiance Empagliflozin Brand 30 $33,759
Eliquis Apixaban Brand 29 $29,389
Wegovy Semaglutide Brand 15 $20,629
Linzess Linaclotide Brand 23 $19,827
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 20 $14,927
Emgality Pen Galcanezumab-Gnlm Brand 14 $13,462

The 10 drugs with the highest cost, of 92 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $270
$270 — —
VRAYLAR
  • AbbVie, Inc. $189
$189 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $150
$150 — —
UBRELVY
  • AbbVie, Inc. $149
$149 — —
REXULTI
  • Lundbeck LLC $57
  • Otsuka America Pharmaceutical, Inc. $51
$109 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record